Benzodiazepines are widely used for their anxiolytic, amnesic, and sedative properties during conscious sedation, and at higher doses, they can induce general anesthesia through potentiation of GABA receptors. When administered acutely, benzodiazepines produce dose-dependent reductions in cerebral blood flow (CBF) and cerebral metabolic rate of oxygen consumption (CMRO₂). This reduction is generally well-matched, reflecting a balanced decrease in both cerebral perfusion and metabolic demand. The effect has a ceiling: midazolam lowers CBF and CMRO₂ by roughly a quarter and cannot drive the EEG to burst suppression the way propofol or barbiturates can, and CO₂ reactivity is preserved. Studies have demonstrated that the modulation of GABAergic activity, which occurs with benzodiazepines, tends to result in decreased CBF, an effect also observed with the non-benzodiazepine GABA modulator zolpidem.
Interestingly, the effects of benzodiazepines on CBF appear to be region-specific, with the largest reductions observed in brain areas associated with memory formation, attention, and arousal, such as the hippocampus and prefrontal cortex. These regions correspond to the clinical effects of benzodiazepines, such as sedation and amnesia, although a direct causal relationship between regional CBF alterations and these effects has not yet been firmly established. Chronic use of benzodiazepines, however, may lead to tolerance to the CBF-reducing effects.
Another point of interest is the role of flumazenil, a benzodiazepine antagonist. Although flumazenil is effective at reversing the sedative effects of midazolam, it does not appear to reverse the CBF reduction in some cases, suggesting that direct vasoconstriction may be involved in the drug’s action. However, conflicting studies report that flumazenil administration does, in fact, restore CBF following benzodiazepine use, leaving this aspect open to further investigation. Flumazenil given to reverse midazolam has raised ICP in head-injured patients, so it is best avoided when intracranial compliance is poor.
